William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Phipps has given his Buy rating due to a combination of factors including the potential of Upstream Bio, Inc.’s TSLP receptor antibody, verekitug, in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The company’s ongoing Phase II study of verekitug, which is expected to report results in the third quarter, is a significant point of interest.
The involvement of key opinion leaders such as Joseph Han, M.D., and the company’s management team in discussions about the treatment landscape and clinical trial endpoints further supports the positive outlook. The recent updates in the CRSwNP treatment landscape, including Phase III data with Tezspire, also highlight the promising potential of Upstream Bio’s therapeutic approach.
In another report released today, J.P. Morgan also maintained a Buy rating on the stock with a $35.00 price target.